Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting

AIDS Patient Care and STDs

Volumn 28, Issue 5, 2014, Pages 221-227

  Mandorfer, Mattias ^a,d   Payer, Berit A ^a,d   Niederecker, Alexander ^a,d   Lang, Gerold ^b,c   Aichelburg, Maximilian C ^b,c   Strassl, Robert ^a,d   Boesecke, Christoph ^c   Rieger, Armin ^b,d   Trauner, Michael ^a,d   Peck Radosavljevic, Markus ^a,d   Reiberger, Thomas ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF BONN   (Germany)

^d Vienna HIV and Liver Study Group   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BOCEPREVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; TELAPREVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; RAPID VIROLOGIC RESPONSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; AUSTRIA; BLOOD; COINFECTION; COMPLICATION; DRUG COMBINATION; GENETICS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; AUSTRIA; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899829423     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0359     Document Type: Article

References (37)

1. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537-1548.
2. Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepatol 2006;44:S6-S9.
3. Reiberger T, Ferlitsch A, Sieghart W, et al. HIV-HCV coinfected patients with low CD4 + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepatitis 2010;17:400-409.
4. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33: 562-569.
5. Norton BL, Park L, McGrath LJ, et al. Health care utilization in HIV-infected patients: Assessing the burden of hepatitis C virus co-infection. AIDS Patient Care STDs 2012;26:541-545.
6. Vogel M, Boesecke C, Rockstroh JK. Acute hepatitis C infection in HIV-positive patients. Curr Opinion Infect Dis 2011;24:1-6.
7. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: A rapidly evolving epidemic. Clin Infect Dis 2012;55:1408-1416.
8. Jonckheere S, Vincent A, Belkhir L, et al. Adherence to screening guidelines for hepatitis C among HIV-positive patients. AIDS Patient Care STDs 2013;27:317-319.
9. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011;60:837-845.
10. Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: A randomized international trial. HIV Clin Trials 2012;13:142-152.
11. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
12. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
13. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
15. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. Ann Intern Med 2013;159:86-96.
16. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13:597-605.
17. Osilla KC, Ryan G, Bhatti L, et al. Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment. AIDS Patient Care STDs 2009;23:993-999.
18. Wagner G, Ryan G, Osilla KC, et al. Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDs 2009;23:715-725.
19. Osilla KC, Wagner G, Garnett J, et al. Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDs 2011;25:533-538.
20. Rutter K, Ferlitsch A, Maieron A, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease-Predictive factors for sepsis. J Hepatol 2013;58:A65.
21. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59: 434-441.
22. Payer BA, Reiberger T, Aberle J, et al. IL28B and interferongamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCVcoinfected patients. Eur J Clin Invest 2012;42:599-606.
23. Theise ND. Liver biopsy assessment in chronic viral hepatitis: A personal, practical approach. Modern Pathol 2007; 20:S3-S14.
24. Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography-A large single center experience. Wien Klin Wochenschr 2012;124:395-402.
25. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
26. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis. Hepatology 2011;53:726-736.
27. Reiberger T, Payer BA, Ferlitsch A, et al. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 2012;17:1327-1334.
28. Hézode C, Dorival C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012;56:217A.
29. HEP-druginteractions.org. (Accessed April 15, 2014).
30. Battegay M, Mulcahy F, Geretti AM, et al. European AIDS Clinical Society (EACS) Guidelines: European AIDS Clinical Society (EACS), 2013.
31. Lontok E, Mani N, Harrington PR, et al. Closing in on the target: Sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clin Infect Dis 2013;56:1466-1470.
32. Reiberger T, Obermeier M, Payer BA, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011;16:815-824.
33. Poveda E, Vispo E, Barreiro P, et al. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. Antivir Ther 2012;17:571-575.
34. Marks M, Kulasegaram R. Drug-drug interactions and drug resistance will limit access to treatment in patients with HIV and hepatitis C virus co-infection. Clin Infect Dis 2013;57:156-157.
35. Mandorfer M, Neukam K, Reiberger T, et al. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. AIDS 2013;27:2707-2714.
36. Mandorfer M, Reiberger T, Payer BA, et al. Revisiting predictors of virologic response to PEGIFN+RBV therapy in HIV-/HCV-coinfected patients: The role of metabolic factors and elevated GGT levels. J Viral Hepat 2014;21:33-41.
37. Mandorfer M, Neukam K, Rivero A, et al. Strategies for assignment of HIV/HCV genotype 1-coinfected patients to either dual-therapy or direct-acting antiviral agent based triple therapy. Antivir Ther 2013 Dec 17. doi: 10.3851/IMP2717. [Epub ahead of print].